Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H1-antihistamine treatment in combination with immunotherapy in advanced non-small cell lung cancer
2022-001284-27Phase 2Active
- Sponsor
- Medical University of Vienna, Department of Internal Medicine I, Division of Oncology
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of fexofenadine in non-small cell lung cancer (NSCLC), sponsored by Medical University of Vienna, Department of Internal Medicine I, Division of Oncology. Primary endpoint: Objective response rate according to RECIST 1.1. Started Jul 2022; status: active.
02
Drugs
fexofenadine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-001284-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001284-27.